Caring for Patients With Hemophilia A in the Midst of a Therapeutic Revolution

Download All
In this comprehensive program centered around an in-person and online live CCO symposium at ASH 2021, experts discuss recent developments in management of hemophilia A. Review their insights in a clinical commentary along with an on-demand webcast and downloadable slides from the symposium. In addition, listen to the audio podcast to hear the experts answer audience questions.
Miguel A. Escobar, MD
Program Director


Factor replacement therapies and newer nonfactor agents offer the ability to tailor therapy for individual patients with hemophilia A. Additional therapies in late-stage development are poised to further alter the treatment landscape. Read an expert’s thoughts on how these new therapies might fit into the existing treatment paradigms in hemophilia A.

Miguel A. Escobar, MD
Program Director
Released: October 14, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Genentech, a member of the Roche Group
Sanofi Genzyme
Takeda Pharmaceuticals U.S.A., Inc.: Takeda Oncology Company

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings